4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥3,740.00
arrow_upward
+0.40%(+15.00) 1D
ኖቬም 10, 10:19:04 ጥዋት ጂ ኤም ቲ+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥3,765
High
JP¥3,770
Low
JP¥3,735
Mkt. cap
174.07 ቢ
Avg. vol.
90.11 ሺ
Volume
10.30 ሺ
Dividend
3.34%
Quarterly dividend
JP¥31
Ex-dividend date
29 ሴፕቴ 2026
P/E ratio
13.86
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
Open
JP¥3,765
High
JP¥3,770
Low
JP¥3,735
Mkt. cap
174.07 ቢ
Avg. vol.
90.11 ሺ
Volume
10.30 ሺ
Dividend
3.34%
Quarterly dividend
JP¥31
Ex-dividend date
29 ሴፕቴ 2026
P/E ratio
13.86
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
News stories
From web sources and news partners
Bloomberg.com
·
ከ3 ሰዓቶች በፊት
Watch S&P 500 Erases Midterm Losses, Bitcoin Bounce
Investing.com
·
ከ3 ሰዓቶች በፊት
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.15%
ChartMill
·
ከ6 ሰዓቶች በፊት
Most-Active S&P 500 Stocks in Today's Session
StoneX
·
ከ9 ሰዓቶች በፊት
S&P 500 Forecast: SPX rises despite Nvidia’s decline
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79 ሺ
Founded9 ኦገስ 1946
HeadquartersMatsumoto, Nagano, ጃፓን
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp